法国某研究所研制了一种流脑菌苗。菌苗是用A群流脑菌株制成,以冰冻形式出售,溶解后即可用于预防注射。在埃及和苏丹用新制流脑菌苗对7万人进行预防接种后,其中没有一个人罹患流脑。菌苗对A群菌株有免疫力,在非洲“流脑地带”发生的流脑主要即由A群引起,其流行区域从苏丹往西,经过撒哈拉大沙漠南部的Sahel地区,直到地处非洲西海岸的塞内加尔。人们估计上述流脑地带在过去30年中的流脑患者约有100万人。 A research institute in France has developed a meningococcal vaccine. Vaccines are made from a group A meningitis strain that is sold in frozen form and ready for injection after being dissolved. None of them suffered from meningitis after 70,000 people were vaccinated with new-borne meningitis vaccine in Egypt and Sudan. The vaccine is immune to the group A strain and the meningitis that occurs in the “meridional zone” of Africa is predominantly caused by group A. Its prevalence ranges from Sudan to the west, through the Sahel region in the southern Sahara until the west coast of Africa Senegal. It is estimated that about 1 million people in the meningitis area have been affected by meningitis in the past 30 years.